Consumer Durables · NSE: SHAILY
Shaily Engineering Plastics
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 30 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹14,321Cr
- P/E
- 76.7×
- 1Y return
- +18.71%
- From 52W high
- −13.9%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 320 | 257 | +24.5% | 281 | +13.8% |
| EBITDA | 97 | 79 | +22.5% | 83 | +17.0% |
| EBITDA margin | 30.4% | 30.9% | -51 bps | 29.6% | +81 bps |
| PBTProfit before tax | 85 | 66 | +28.7% | 66 | +28.2% |
| Net profit | 61 | 51 | +19.6% | 48 | +27.6% |
| EPS (₹) | 13.27 | 11.12 | +19.3% | 10.41 | +27.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY27 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.
Guidance
Healthcare: Management expects to exceed device guidance but cannot say by how much
Amit Sanghvi · Managing Director · Q&A · p. 10
Healthcare: Management expects to exceed device guidance but cannot say by how much
“I think we will exceed the guidance. Now how much we exceed it by, I have no clue.”
Healthcare: FY28 devices: analyst's figure, give or take 15%, targeted; management says it is not guidance
Amit Sanghvi · Managing Director · Q&A · p. 13
Healthcare: FY28 devices: analyst's figure, give or take 15%, targeted; management says it is not guidance
“As far as next year is concerned, the number you stated, give or take, 15% is what we're targeting. Could be higher, could be lower. We don't know again. It's not a guidance.”
More figures from the call
“I think we're close to finalizing a customer for the on-body Mira, post which we will have a 14-month time line to deliver clinical batches”
“I'm fairly confident that, yes, by the end of calendar '27, we should be able to crack 1 or 2 innovators.”
“I think the split this year at the end of the year was likely to look at potentially 70-30.”
“So I think right now, you have about 3 or 4 molecules on on-body injectors. The one that is going to be targeted by generics is Neulasta.”
In short
- 01Q2 FY27 revenue was INR320 crores, up 24% year-on-year; EBITDA INR102 crores at 31.9% margin.
- 02Healthcare was 55% of revenue and grew 78% year-on-year, led by GLP-1 pen programs.
- 03Management expects to exceed its FY27 guidance of 36 million devices; 10.4 million delivered in Q2.
- 04New pen capacity starts qualification next week, with sales from it expected in December.
- 05Consumer revenue fell 14% year-on-year; management expects it to stay flat this year.
- 06Semiconductor shipments are expected from Q4 FY27; Consumer Electronics capex seen at about INR100 crores.
- 07Management expects to maintain margins despite pen price erosion, citing operating leverage still to come.
- 08Management expects to win 1 or 2 innovator customers by end of calendar 2027, with revenue 3-4 years later.
Capex
Consumer Electronics and Semiconductor Packaging: Capacity expansion to be aligned with customer commitments
Amit Sanghvi · Managing Director · p. 5
Consumer Electronics and Semiconductor Packaging: Capacity expansion to be aligned with customer commitments
“Our approach will remain measured and disciplined, with the capacity expansion aligned to customer commitments and the pace of business development.”
Capacity
Healthcare: New pen capacity starts qualification next week; sales from it expected in December
Amit Sanghvi · Managing Director · Q&A · p. 11
Healthcare: New pen capacity starts qualification next week; sales from it expected in December
“So it starts qualification next week. If all goes well, we should be in a position to start selling from that capacity in December.”
Semiconductor: Small semiconductor capacity to start; more to be added once supplies begin
Sanjay Shah · Chief Strategy Officer · Q&A · p. 16
Semiconductor: Small semiconductor capacity to start; more to be added once supplies begin
“But the take is we are setting up a small capacity to start with. And if we start supplying, we understand the demand, we will add more capacity.”
Healthcare: Neo line installed; qualifications begin next week
Amit Sanghvi · Managing Director · Q&A · p. 9
Healthcare: Neo line installed; qualifications begin next week
“We've just installed the Neo line, which we are now getting into qualifications next week.”
Healthcare: Healthcare capacity being scaled, including through the Abu Dhabi facility
Amit Sanghvi · Managing Director · p. 4
Healthcare: Healthcare capacity being scaled, including through the Abu Dhabi facility
“With established partnerships across multiple customers and geographies, we are strengthening our platforms and scaling capacity, including through our Abu Dhabi facility to capture this next phase of market growth.”
Order book
Industrial: Industrial: business confirmed for 7 new power tool products and new appliance knobs
Amit Sanghvi · Managing Director · p. 5
Industrial: Industrial: business confirmed for 7 new power tool products and new appliance knobs
“During the quarter, we received business confirmation for 7 new power tool products and new knobs from an Appliance customer.”
Segments
Healthcare: Healthcare contributed 55% of revenue and grew 78% year-on-year
Amit Sanghvi · Managing Director · p. 3
Healthcare: Healthcare contributed 55% of revenue and grew 78% year-on-year
“Healthcare is now the primary engine of our business, contributing 55% of revenue and growing 78% year-on-year.”
Consumer: Consumer business stabilised over two quarters but remains below last year's levels
Amit Sanghvi · Managing Director · p. 3
Consumer: Consumer business stabilised over two quarters but remains below last year's levels
“Third, the Consumer business has finally stabilized over two sequential quarters, although it continues to operate below last year's levels.”
Healthcare: Platforms being extended beyond GLP-1 into emergency use and oncology
Amit Sanghvi · Managing Director · p. 4
Healthcare: Platforms being extended beyond GLP-1 into emergency use and oncology
“We are also extending our platforms beyond GLP-1 into new therapeutic areas with a particular focus on emergency use and oncology.”
Consumer: Q2 Consumer revenue INR116 crores, down 14% year-on-year
Amit Sanghvi · Managing Director · p. 5
Consumer: Q2 Consumer revenue INR116 crores, down 14% year-on-year
“Consumer revenue was INR116 crores, down 14% year-on-year.”
Consumer: Consumer: new product from one customer and higher volumes from another confirmed
Amit Sanghvi · Managing Director · p. 5
Consumer: Consumer: new product from one customer and higher volumes from another confirmed
“During the quarter, we received business confirmation for a new product from an existing customer and for higher volumes of an existing product from another customer.”
Demand
Healthcare: Demand for drug delivery devices expected to grow as GLP-1 affordability improves
Amit Sanghvi · Managing Director · p. 4
Healthcare: Demand for drug delivery devices expected to grow as GLP-1 affordability improves
“As affordability improves and patient access expands, demand for drug delivery devices is expected to grow.”
Consumer: Consumer demand in Europe and the US described as weak
Sanjay Shah · Chief Strategy Officer · Q&A · p. 16
Consumer: Consumer demand in Europe and the US described as weak
“Consumer demand in Europe and the U.S. is weak.”
Healthcare: Management says healthcare demand is strong, even stronger
Amit Sanghvi · Managing Director · Q&A · p. 9
Healthcare: Management says healthcare demand is strong, even stronger
“No, our demand is strong, even stronger, to be honest.”
Healthcare: Over 1 billion auto-injectors a year end up in landfill for two large GLP-1 brands
Amit Sanghvi · Managing Director · Q&A · p. 8
Healthcare: Over 1 billion auto-injectors a year end up in landfill for two large GLP-1 brands
“you'd be looking at a global auto-injector consumption of over 1 billion injectors that end up in the landfill every year.”
Healthcare: Generic GLP-1 product launched in only 3 markets so far
Amit Sanghvi · Managing Director · Q&A · p. 13
Healthcare: Generic GLP-1 product launched in only 3 markets so far
“Markets are still launching. So at the moment, you only have 3 markets where the product is launched.”
Margins and costs
Q2 EBITDA rose 25% year-on-year to INR102 crores at a 31.9% margin
Amit Sanghvi · Managing Director · p. 3
Q2 EBITDA rose 25% year-on-year to INR102 crores at a 31.9% margin
“EBITDA rose 25% year-over-year and 22% sequentially to INR102 crores at a margin of 31.9%.”
Gross margin recovered to 60%, about 70 bps higher than a year ago
Amit Sanghvi · Managing Director · p. 3
Gross margin recovered to 60%, about 70 bps higher than a year ago
“Second, gross margins recovered to 60%, about 70 basis points higher than a year ago, following the cost pressures we highlighted in quarter 1.”
Healthcare: Toby Reusable expected to carry same or possibly higher profitability
Amit Sanghvi · Managing Director · Q&A · p. 8
Healthcare: Toby Reusable expected to carry same or possibly higher profitability
“So we have a very nice solution where I think you maintain either same or higher possibly profitability, but providing a very, very unique solution to the customer”
Healthcare: Higher average device price due to GLP replacing insulin contract work
Sanjay Shah · Chief Strategy Officer · Q&A · p. 13
Healthcare: Higher average device price due to GLP replacing insulin contract work
“So that capacity has been replaced by GLP, but the realizations would be higher.”
Healthcare: Pen pricing pressure exists; price erosion already built into long-term contracts
Amit Sanghvi · Managing Director · Q&A · p. 14
Healthcare: Pen pricing pressure exists; price erosion already built into long-term contracts
“There is pricing pressure. And for all the long-term contracts that we currently have in place, a) price erosion has already been built into that contract.”
Debt and working capital
CARE reaffirmed long-term rating at A+ stable; short-term upgraded to A1+
Sanjay Shah · Chief Strategy Officer · p. 6
CARE reaffirmed long-term rating at A+ stable; short-term upgraded to A1+
“In October, CARE Ratings reaffirmed our long-term bank facilities at CARE A+ with a stable outlook and upgraded our short-term facilities to CARE A1+ from CARE A1.”
ROCE 41.1%, ROE 29.7%, debt to equity 0.2x at 30 September 2026
Sanjay Shah · Chief Strategy Officer · p. 6
ROCE 41.1%, ROE 29.7%, debt to equity 0.2x at 30 September 2026
“ROCE and ROE were at 41.1% and 29.7%, respectively, as of 30th September 2026. Debt to equity was 0.2x, and the fixed asset turnover was 2x as of 30th September 2026.”
Acquisitions and new business
Healthcare: Two new platform contracts signed; Toby Reusable auto-injector launched
Amit Sanghvi · Managing Director · p. 4
Healthcare: Two new platform contracts signed; Toby Reusable auto-injector launched
“During the quarter, we signed 2 new contracts for these platforms and launched our latest innovation, the Toby Reusable auto-injector”
Semiconductor: Semiconductor tray revenue on track to start in Q4 '27 from existing facility
Amit Sanghvi · Managing Director · p. 5
Semiconductor: Semiconductor tray revenue on track to start in Q4 '27 from existing facility
“Semiconductor Tray revenue remains on track to commence in Q4 '27 from our existing facility.”
Semiconductor Packaging: Semiconductor packaging trial production in Q3 FY27, commercial shipments expected in Q4
Amit Sanghvi · Managing Director · p. 5
Semiconductor Packaging: Semiconductor packaging trial production in Q3 FY27, commercial shipments expected in Q4
“We would start trial production of Semiconductor Packaging in Q3 FY27, expect to start commercial shipments in Q4.”
Healthcare: Toby Emergency Use: 2 customers, clinical batches end '27, earliest commercial end of 2028
Amit Sanghvi · Managing Director · Q&A · p. 7
Healthcare: Toby Emergency Use: 2 customers, clinical batches end '27, earliest commercial end of 2028
“We have 2 active customers on emergency use for whom we are developing this product. From a time line perspective, the clinical batches are due end of '27, which means that earliest commercialization to production will be probably end of calendar '28.”
Healthcare: Toby Reusable does not cannibalise existing products, management says
Amit Sanghvi · Managing Director · Q&A · p. 8
Healthcare: Toby Reusable does not cannibalise existing products, management says
“So a) it doesn't cannibalize any of our existing product portfolio”
One-offs
Higher other expenses mix one-off costs and business-mix related increases
Sanjay Shah · Chief Strategy Officer · Q&A · p. 11
Higher other expenses mix one-off costs and business-mix related increases
“So it's a combination of one-off expenses and some increase in expenses.”
Risks
West Asia events affected freight and polymer prices; Europe and US home furnishing demand subdued
Amit Sanghvi · Managing Director · p. 3
West Asia events affected freight and polymer prices; Europe and US home furnishing demand subdued
“Development in West Asia continued to impact freight cost and polymer prices, while demand for home furnishings in Europe and the U.S. remained subdued.”
Healthcare: Pressure on capacity ramp-up is easing but not resolved
Amit Sanghvi · Managing Director · Q&A · p. 10
Healthcare: Pressure on capacity ramp-up is easing but not resolved
“It's easing off. It has not eased off. So it's still work in progress.”
Healthcare: Recall over dose labelling not attributable to Shaily, management says
Amit Sanghvi · Managing Director · Q&A · p. 8
Healthcare: Recall over dose labelling not attributable to Shaily, management says
“This has no bearing or there's nothing attributed to Shaily for this particular recall.”
Other
Q2 FY27 consolidated revenue INR320 crores, up 24% year-on-year and 14% sequentially
Amit Sanghvi · Managing Director · p. 3
Q2 FY27 consolidated revenue INR320 crores, up 24% year-on-year and 14% sequentially
“Consolidated revenue for Q2 FY27 was INR320 crores, up 24% year-on-year and 14% sequentially.”
Healthcare: Initial assessment: Toby Reusable is 70% more sustainable than a disposable auto-injector
Amit Sanghvi · Managing Director · p. 4
Healthcare: Initial assessment: Toby Reusable is 70% more sustainable than a disposable auto-injector
“Our initial assessments indicate that conservatively, it is 70% more sustainable than a disposable two-step auto-injector.”
Exports were 62.9% of H1 FY27 revenue versus 71.7% in H1 FY26
Sanjay Shah · Chief Strategy Officer · p. 6
Exports were 62.9% of H1 FY27 revenue versus 71.7% in H1 FY26
“Exports accounted for 62.9% of revenue in H1 FY27 compared to 71.7% in H1 FY26.”
Healthcare: Export share fell because Healthcare growth comes via Indian pharma customers
Sanjay Shah · Chief Strategy Officer · p. 6
Healthcare: Export share fell because Healthcare growth comes via Indian pharma customers
“The shift is primarily attributable to growth in the Healthcare business where we supply Indian pharma customers who, in turn, serve global markets.”
Q2 PAT INR61 crores versus INR51 crores, up 20%
Sanjay Shah · Chief Strategy Officer · p. 6
Q2 PAT INR61 crores versus INR51 crores, up 20%
“Profit after tax was INR61 crores compared with INR51 crores in Q2 FY26, up 20%.”
Sources
- Earnings call transcript, Q2 FY27 Filed 6 Nov 2026 · 17 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

